Nachrichten zur Agios Pharmaceuticals Inc. Aktie

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building…

Agios Pharmaceuticals (AGIO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Unusual Options Activity Insight: Agios Pharmaceuticals

On Friday, shares of Agios Pharmaceuticals (NASDAQ: AGIO) saw unusual options activity. After the option alert, the stock price moved…

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

Agios Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals Inc (AGIO) Q3 2020 Earnings Call Transcript

AGIO earnings call for the period ending October 31, 2020....…

AGIOS PHARMACEUTICALS, INC.: 10-Q Report

10-Q...…

Agios Pharmaceuticals EPS misses by $0.06, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals Q3 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host…

Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…

Agios: A Look At Mitapivat In Anaemia, Its Backup Indication

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU

Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in…

Agios: A Look At TIBSOVO In CC Patients

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios falls after pulling European marketing application for Tibsovo

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients –...…

All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to Buy

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…

Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

– Supplemental New Drug Application Planned for Submission in Q1 2021 –...…

New finance chief at Agios Pharmaceuticals

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs

Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain…

Agios Pharmaceuticals A Buy For Tibsovo, Mitapivat

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020

CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…

Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript

AGIO earnings call for the period ending June 30, 2020....…

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AGIOS PHARMACEUTICALS, INC.: 10-Q Report

10-Q...…

Agios Pharmaceuticals, Inc. 2020 Q2 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do…

Agios Reports Business Highlights and Second Quarter 2020 Financial Results

– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million –...…

Agios Pharma CEO Jackie Fouse Looks Ahead After Lackluster Start

Agios Pharma CEO Jackie Fouse Looks Ahead After Lackluster Start...…

Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020

CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…

Agios Pharmaceuticals (AGIO) Presents At European Hematology Association Congress - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty

– Royalty Pharma Acquires Rights to Agios Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments –...…

Agios reports positive mitapivat data in sickle cell disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia

The FDA confers an orphan drug status on Agios (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock…

Thermo Fisher teams up with Agios on second companion diagnostic

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia

CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Moving Average Crossover Alert: Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable…

Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year-

Is (AGIO) Outperforming Other Medical Stocks This Year?...…

Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant…

Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation –...…

Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

– Company to Present Additional Clinical Data Supporting Utility of TIBSOVO® in Cholangiocarcinoma and AML – – Company to Present…